Back to today’s briefing

Story perspectives

FDA Approves Elecsys pTau217 Blood Test for Alzheimer’s

9/4/2026

12 2 Full Breakdown

Summary

Story summary

U.S. FDA approved Roche-Eli Lilly’s Elecsys pTau217 blood test for Alzheimer’s.
The test measures plasma pTau217, a tau protein that rises early and mirrors amyloid.
It can confirm or rule out amyloid pathology in adults 55 + with cognitive symptoms.
MRI scans showed cortical-thickness changes at least seven years before plaques appear on PET.
The two-decade MRI study compared older adults who later developed plaques with those who did not.

1 of 1

Story summary

U.S. FDA approved Roche-Eli Lilly’s Elecsys pTau217 blood test for Alzheimer’s.
The test measures plasma pTau217, a tau protein that rises early and mirrors amyloid.
It can confirm or rule out amyloid pathology in adults 55 + with cognitive symptoms.
MRI scans showed cortical-thickness changes at least seven years before plaques appear on PET.
The two-decade MRI study compared older adults who later developed plaques with those who did not.